Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $113.98 +2.11%
EPS Growth %: +393.8%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $100.62 million.
GUIDANCE:
Corcept Therapeutics sees FY2022 revenue of $400-430 million, versus the consensus of $414.4 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- Braze stock tumbles 10% on weak third quarter EPS guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
